Granahan Investment Management LLC Increases Stock Position in SiBone $SIBN

Posted by Brian Himes on Jul 25th, 2026

Granahan Investment Management LLC lifted its position in shares of SiBone (NASDAQ:SIBN – Free Report) by 97.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,739,097 shares of the company’s stock after purchasing an additional 858,942 shares during the period. SiBone makes up approximately 1.1% of Granahan Investment Management LLC’s holdings, making the stock its 26th biggest holding. Granahan Investment Management LLC’s holdings in SiBone were worth $21,965,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in SiBone during the first quarter valued at about $225,000. Goldman Sachs Group Inc. increased its stake in SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after acquiring an additional 83,919 shares during the last quarter. Jane Street Group LLC acquired a new stake in SiBone during the first quarter worth about $1,818,000. Finally, Legal & General Group Plc raised its holdings in shares of SiBone by 16.1% in the 2nd quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after purchasing an additional 5,888 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at SiBone

In related news, CEO Laura Francis sold 14,957 shares of SiBone stock in a transaction on Monday, May 18th. The shares were sold at an average price of $14.71, for a total transaction of $220,017.47. Following the sale, the chief executive officer owned 503,444 shares of the company’s stock, valued at $7,405,661.24. The trade was a 2.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Michael A. Pisetsky sold 3,726 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $14.63, for a total transaction of $54,511.38. Following the completion of the transaction, the senior vice president owned 280,509 shares in the company, valued at $4,103,846.67. This represents a 1.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 36,326 shares of company stock valued at $545,661. 4.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SIBN has been the topic of several research analyst reports. TD Cowen reduced their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Truist Financial increased their target price on shares of SiBone from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.50.

Check Out Our Latest Research Report on SiBone

SiBone Stock Performance

SiBone stock opened at $16.62 on Friday. The stock’s 50 day moving average price is $15.92 and its 200 day moving average price is $15.24. The firm has a market capitalization of $737.08 million, a PE ratio of -42.62 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The firm had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. As a group, sell-side analysts expect that SiBone will post -0.44 EPS for the current fiscal year.

SiBone Company Profile

(Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.